Invivyd reported a quarterly loss of $0.13 per share, wider than the Zacks Consensus Estimate of a $0.08 loss and slightly worse than the $0.14 loss a year ago. The result is a modest earnings miss for the biotech company, indicating continued pressure on profitability. The update is likely to weigh on the stock, though the impact should be limited to the individual name.
Invivyd reported a quarterly loss of $0.13 per share, wider than the Zacks Consensus Estimate of a $0.08 loss and slightly worse than the $0.14 loss a year ago. The result is a modest earnings miss for the biotech company, indicating continued pressure on profitability. The update is likely to weigh on the stock, though the impact should be limited to the individual name.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment
